期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 157, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103179
关键词
hepatocellular carcinoma; liver cancer; systemic treatment; sorafenib; immunotherapy
In recent years, there have been significant changes in the landscape of HCC treatment, with small molecule inhibitors being the core of treatment while immunotherapy is emerging as a promising option.
According to data provided by WHO (World Health Organization), hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Since the approval of sorafenib in 2008, several trials have assessed other particles for the treatment of HCC, but few have proven to be effective. ESMO (European Society for Medical Oncology) guidelines have been changed several times recently. This systematic review aims to describe both successful and failed trials of systemic treatments for HCC. Methods: We examined randomized, phase III trials of firstand second-line treatments in adults, identifying 23 fully-published trials and 2 reported as abstracts. The latest advances in immunotherapy were also briefly discussed. Conclusions: The landscape of HCC treatment has changed significantly in recent years. Several small molecule inhibitors currently form the core of HCC treatment; however, immunotherapy is now emerging as a promising treatment option.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据